Skip to main content

Clinical Trials Using Trastuzumab Deruxtecan

Review the clinical trials studying trastuzumab deruxtecan on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 39

Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 125 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 33 locations
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Status: Active
Location: 21 locations
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Status: Active
Location: 18 locations
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers with Changes in the HER2 Gene
Status: Active
Location: 18 locations
Trastuzumab Deruxtecan for the Treatment of HER2 Immunohistochemistry 0 Unresectable or Metastatic Breast Cancer
Status: Active
Location: 12 locations
Datopotamab Deruxtecan and Trastuzumab Deruxtecan for the Treatment of HER2-Negative Unresectable, Locally Advanced or Metastatic Breast Cancer
Status: Active
Location: 10 locations
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Status: Active
Location: 9 locations
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Status: Active
Location: 8 locations
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Status: Active
Location: 7 locations
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Status: Active
Location: 8 locations
Trastuzumab Deruxtecan Before Surgery for the Treatment of Patients with Brain Cancer, WONDER-BT Trial
Status: Active
Location: 7 locations
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Status: Active
Location: 6 locations
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Status: Active
Location: 7 locations
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Status: Active
Location: 6 locations
PRE-I-SPY Phase I/Ib Oncology Platform Program
Status: Active
Location: 7 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 4 locations
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Status: Active
Location: 5 locations
SNV1521 in Participants with Advanced Solid Tumors
Status: Active
Location: 4 locations
Trastuzumab Deruxtecan and Durvalumab Before Surgery for the Treatment of Patients with Stage III, HER2-Expressing Inflammatory Breast Cancer
Status: Active
Location: 3 locations
Trastuzumab Deruxtecan Alone, in Combination with Anastrozole, or Followed by Chemotherapy for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Status: Active
Location: 4 locations
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Status: Active
Location: 2 locations
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Status: Active
Location: 2 locations